▲ +43.37% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vivos Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 43.37% upside from the last price of $8.37.
The current consensus among 2 investment analysts is to buy stock in Vivos Therapeutics.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. It caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers, and patients in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2007 and is based in Highlands Ranch, Colorado.